Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|March 31, 2023

Drug Digest Editorial Interview Series: Fundamental Constriction Points in Emerging Therapies, High-Titre Vector-Producing Cells: Part 3

Benjamin McLeod, Technical Lead, Virica Biotech, speaks about fundamental constriction points in emerging therapies, high-titre vector-producing cells.

Benjamin serves as Technical Lead with Virica Biotech, a yield-enhancing solution for viral vector and cell therapy production. He is trained in cell biology, biotechnology, and viral vector production. You can find him on LinkedIn, where he regularly posts industry insights and curates papers on process development in CGT.

Register for the full webcast: https://www.pharmtech.com/pt_w/high-titre


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.